Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lars Lööf is active.

Publication


Featured researches published by Lars Lööf.


Gut | 2004

Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome

Gudjón Kristjánsson; Per Venge; Alkwin Wanders; Lars Lööf; Roger Hällgren

Background and aims: There is a clear need for a rapid, simple, safe, and sensitive method of determining the type and intensity of inflammation in the gut mucosa in clinical practice. In this study, we have evaluated the potential of a new method, the mucosal patch technique, in patients with and without apparent gut inflammation, as assessed by conventional diagnostic procedures. Subjects and methods: The technique tested is based on the idea that inflammatory mediators released from the rectal mucosa can be absorbed by and then extracted from cellulose patches brought into contact with the mucosa by use of an instrument with an inflatable balloon. Measurements were performed in healthy controls (n = 16) and in patients with active (n = 19) and inactive ulcerative colitis (UC, n = 8), collagen colitis (CC, n = 12), coeliac disease (n = 13), and irritable bowel syndrome (IBS, n = 13). Results: Inflammatory mediators from neutrophils (myeloperoxidase (MPO)) and eosinophils (eosinophil cationic protein (ECP)) were increased on average 300- and 10-fold, respectively, in patients with active UC compared with healthy controls and were correlated with the endoscopic score. Patients with inactive UC, CC, coeliac disease, and IBS exhibited no endoscopic signs of inflammation. These patient groups had significantly lower levels of MPO and ECP than the active UC group but showed on average a four- to sevenfold increase in MPO compared with healthy controls. Conclusion: The mucosal patch technique was well tolerated by patients and easily applied by the investigator. Pronounced neutrophil and eosinophil involvement in UC was demonstrated. With the high sensitivity of the technique, low degree mucosal neutrophil activation could also be quantified in patients with CC and UC in clinical remission. The finding of increased neutrophil involvement in patients with IBS contributes to the pathophysiological ideas of this disease.


Digestive Diseases and Sciences | 2001

IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis.

Maria Lampinen; Marie Carlson; Per Sangfelt; Yesuf Taha; T. Magnus Thörn; Lars Lööf; Yngve Raab; Per Venge

There is an increased influx of activated eosinophils to the intestinal mucosa in active ulcerative colitis, and an increased release of eosinophil-derived proteins, such as ECP, has also been observed. These findings indicate that eosinophils may contribute to tissue damage and intestinal inflammation in this disease. The relative importance of different chemotactic factors and the impact of steroid treatment on their effect in active ulcerative colitis are not known. We measured the eosinophil chemotactic activity in perfusion fluids from 11 patients with ulcerative colitis before and after steroid treatment and from 7 control patients. The effect of neutralizing antibodies to IL-5 and -8, RANTES, eotaxin, MCP-3, TNF-α, GM-CSF was investigated. The chemotactic activity was higher in perfusion fluids from patients than from controls (P = 0.0043). Anti-IL-5 (P = 0.005) and -TNF-α (P = 0.017) inhibited the activity in perfusion fluids obtained before treatment. Steroid treatment prevented the effect of all antibodies but had no significant effect on the chemotactic activity. The chemotactic activity correlated with the levels of eosinophil granule proteins in the perfusion fluids. In conclusion, in ulcerative colitis, eosinophils are attracted to the intestinal tissue by chemotactic factors, of which IL-5 and TNF-α may be the most prominent steroid-sensitive ones. The steroid-insensitive chemotactic activities remain unidentified.


The American Journal of Medicine | 1989

Challenge with gliadin induces eosinophil and mast cell activation in the jejunum of patients with celiac disease

Bengt Lavō; Lars Knutson; Lars Lööf; Bo Odlind; Per Venge; Roger Hällgren

PURPOSE The aim of this study was to clarify the role of eosinophils and mast cells in the small bowel in celiac disease. PATIENTS AND METHODS Patients with celiac disease (n = 10) were investigated by perfusion of a closed jejunal segment. The concentrations of certain granule constituents from eosinophils, eosinophil cationic protein (ECP), and from mast cells/basophils, histamine, were measured and the jejunal secretion rates of these cellular markers were calculated. RESULTS Compared with findings in healthy control subjects (n = 14), increased secretion rates were observed under basal conditions in patients with histopathologically active celiac disease. Gliadin, administered by perfusion to the jejunal segment, induced a fourfold increase in ECP secretion and a twofold increase of histamine secretion in patients with celiac disease (n = 7), but did not influence the secretion rates of these substances in healthy controls (n = 3). The secretion rate of ECP started to increase 20 minutes after challenge of the perfused segment with gliadin and reached maximum levels 40 minutes later. The secretion rate of histamine started to increase 40 minutes after gliadin administration. Concurrently with these inflammatory events, the secretion of albumin was doubled as a sign of increased mucosal leakage. CONCLUSION These data indicate that eosinophils and mast cells are both involved in the early gliadin-induced reactions of the small intestine, and suggest that these cells are effector cells participating in the celiac lesion of the mucosa.


Upsala Journal of Medical Sciences | 1984

Primary Biliary Cirrhosis—Phenotypic Characterization of Immunocompetent Cells in Peripheral Blood and Liver Tissue

Alex Karlsson-Parra; Anders Nyberg; Thomas H. Tötterman; Lars Lööf; Urban Forsum

Circulating T-cell subsets have been characterized in 18 patients with primary biliary cirrhosis (PBC) using a simple immunoenzymatic staining method on stored and prefixed cell samples. Furthermore, a double immunoenzymatic method was used to study T-cell subsets and their relationship to HLA-DR+ cells in frozen sections of liver biopsies from 12 patients with PBC. In 10 cases blood and liver samples were taken simultaneously from the same patient. Patients with PBC of early histological stage showed an elevated absolute number of helper/inducer T-cells (Leu 3a+) and reduced relative percentages of suppressor/cytotoxic T-cells (Leu 2a+) compared with healthy subjects resulting in an elevated helper/suppressor ratio. Liver biopsies in PBC were dominated by helper inducer phenotype T-cells in all cases irrespective of histological stage, penicillamine treatment or the relative levels of circulating T-cell subsets. A relatively high amount of HLA-DR+ cells were seen, several of these in close approximation to T-cells.


Hepatology | 1985

Increased serum levels of hyaluronate in liver disease.

Anna Engström-Laurent; Lars Lööf; Anders Nyberg; Torbjörn Schröder


British Journal of Clinical Pharmacology | 2005

Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract

Mari Thörn; Niklas Finnström; Stefan Lundgren; Anders Rane; Lars Lööf


Hepatology | 1988

Serum hyaluronate in primary biliary cirrhosis--a biochemical marker for progressive liver damage.

Anders Nyberg; Anna Engström-Laurent; Lars Lööf


Hepatology | 1988

Impaired release of vitamin a from liver in primary biliary cirrhosis

Anders Nyberg; Berit Berne; Hans Nordlinder; Christer Busch; Ulf J. Eriksson; Lars Lööf; Anders Vahlquist


Biochimica et Biophysica Acta | 1978

Enzymatic sulphation of bile salts in human liver.

Lars Lööf; Bo Wengle


Biochimica et Biophysica Acta | 1980

Partial purification of a human liver sulphotransferase active towards bile salts

Lars Lööf; Stellan Hjertén

Collaboration


Dive into the Lars Lööf's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Niklas Finnström

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yesuf Taha

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge